The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid ongoing growth in the emerging medical imaging sector, Nanox (NNOX) reported Q1 2026 results showing a 54% year-over-year revenue increase. According to preliminary company data, revenue reached $4.3 million compared to $2.8 million in Q1 2025, reflecting commercial expansion despite the absence of profitability data.
The growth comes at a time when the medical imaging sector faces competitive pressures, with peers such as Butterfly Network and Siemens Healthineers showing mixed performance recently. However, no direct profitability comparisons are available, limiting the ability to assess Nanox's relative performance.
In trading, NNOX closed at $1.67 on June 18, 2026, impacted by a broader downturn in small-cap stocks. No near-term catalysts are clearly visible, though markets await updates on the rollout of the novel "Nanox.ARC" imaging technology and annual revenue guidance.
Sign in to access this content
Sign In